Webinar: Scaling mRNA Therapeutics from Research to cGMP
Get access today!
| region | na1 |
| portalId | 1769030 |
| formId | 11bdc374-6e4d-4573-9c3e-6729f05df0bc |
| target | services-hubspot-form |
| redirectUrl | https://www.aldevron.com/thank-you/on-demand-scaling-mrna-therapeutics-research-grade-cgmp |
How to avoid tech transfer pitfalls and optimize template design, QC, and DNA workflows for scalable, consistent mRNA production
This webinar focuses on the high-impact decisions that determine whether an RNA program advances or stalls during tech transfer. We will explore how template design and process optimization influence purity, reproducibility, and overall development performance. A key focus will be the role of cell-free enzymatic DNA platforms in bypassing the limitations of traditional microbial upstream processes to reduce host cell components while significantly compressing development timelines.
Key Learning Objectives
- Identify early-stage pitfalls specific to mRNA, including: template quality, IVT variability, dsRNA formation, capping and poly(A) control.
- Apply phase-appropriate material selection for linear DNA templates, including when and how to transition from research grade to cGMP materials while preserving comparability.
- Design fit-for-purpose QC and analytical strategies for mRNA (e.g., integrity, dsRNA, 5′ cap, poly(A) tail, residual DNA and enzymes) to maintain consistent product quality as batches scale.
- Plan for supply-chain and process scalability, including evaluation of enzymatic, cell-free linear DNA synthesis technologies to reduce lead times and variability from research through cGMP.